BiotechTube

AG-348

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pyruvate Kinase Deficiency

Conditions

Pyruvate Kinase Deficiency

Trial Timeline

Jun 26, 2015 → Apr 2, 2025

NCT ID
NCT02476916

About AG-348

AG-348 is a phase 2 stage product being developed by Agios Pharmaceuticals for Pyruvate Kinase Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT02476916. Target conditions include Pyruvate Kinase Deficiency.

What happened to similar drugs?

1 of 6 similar drugs in Pyruvate Kinase Deficiency were approved

Approved (1) Terminated (0) Active (5)
🔄Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
🔄Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
🔄MitapivatAgios PharmaceuticalsPhase 3
🔄Placebo + AG-348Agios PharmaceuticalsPhase 3
✅MitapivatAgios PharmaceuticalsApproved
🔄AG-348Agios PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT04000165Phase 1Completed
NCT03692052Phase 2Active
NCT03559699Phase 3Completed
NCT02476916Phase 2Completed

Competing Products

9 competing products in Pyruvate Kinase Deficiency

See all competitors
ProductCompanyStageHype Score
TriheptanoinUltragenyx PharmaceuticalPhase 1
30
Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
38
Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
38
MitapivatAgios PharmaceuticalsPhase 3
34
Placebo + AG-348Agios PharmaceuticalsPhase 3
34
MitapivatAgios PharmaceuticalsApproved
44
AG-348Agios PharmaceuticalsPhase 3
34
RP-L301Rocket PharmaceuticalsPhase 1
19
RP-L301Rocket PharmaceuticalsPhase 2
32